Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non –small cell lung cancer patients with asymptomatic brain metastases

Conclusion: Ramucirumab in combination with erlotinib or osimertinib showed safety forEGFR-mutated NSCLC with brain metastases.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research